Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body, and its symptoms range from general malaise to serious, CNS and renal manifestations. Currently, there are limited treatment options available to treat the condition. Corticosteroids, hydroxychloroquine, and conventional immunosuppressants are the mainstay of treatment for SLE. However, many patients fail to respond to these therapies and/or experience significant adverse events, and clinicians utilize other agents including Benlysta (the only biologic indicated for SLE) and Rituxan (off-label).
The Treatment Algorithms: Claims Data Analysis report examines physicians’ actual prescribing behavior as they initiate therapy and move through second- and third-line choices. Our analysis is supported by a deep longitudinal patient-level claims dataset and provides a representative sample of U.S. treatment practice for Medicare supplemental and commercially insured patients.
- Which therapies capture the top patient share in different lines of therapies for both newly diagnosed and recently treated patients?
- What proportion of SLE patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- Which therapies are used alone and which ones are used in combination? What are the most widely used combination therapies?
- What percentage of newly diagnosed patients on key SLE therapies add or switch to new agents as they move through lines of treatment?
- What are the persistency and compliance rates for key SLE therapies?